Recovery & Performance Clinic Kit

BPC-157 is a synthetic 15-amino acid fragment derived from human gastric body protection compound. It promotes angiogenesis by upregulating VEGF and its receptor VEGFR2, activates the FAK-paxillin pathway to enhance cell migration and wound closure, and modulates the nitric oxide system. It also interacts with the dopaminergic system and has cytoprotective effects on gastrointestinal mucosa, tendons, ligaments, and other connective tissues.

TB-500 (synthetic thymosin beta-4) is studied for its role in actin dynamics, a core process that helps cells migrate, reorganize, and respond to repair signals. Published literature has examined its interaction with angiogenic signaling, inflammatory pathways, and tissue-remodeling biology across multiple preclinical models. The active region LKKTETQ is considered central to its actin-binding activity.

Mod GRF 1-29 is a modified 29-amino acid fragment of GHRH with four amino acid substitutions that prevent enzymatic degradation: D-Ala2 prevents DPP-IV cleavage, Gln8 prevents asparagine rearrangement, Ala15 enhances bioactivity, and Leu27 prevents methionine oxidation. Without the DAC moiety, it produces more physiologic pulsatile GH release patterns, stimulating somatotrophs through GHRH receptors with a much shorter duration of action.

Ipamorelin is a highly selective growth hormone secretagogue that acts on the ghrelin/GHS receptor (GHSR) in the pituitary to stimulate pulsatile GH release. Unlike other GHRPs, ipamorelin does not significantly affect cortisol, ACTH, or prolactin levels at GH-releasing doses, making it the most selective GHS available. It works synergistically with GHRH analogs (like CJC-1295) to amplify GH pulses while maintaining the natural pulsatile release pattern.

MK-677 is an orally active, non-peptidic ghrelin receptor (GHSR-1a) agonist that mimics the GH-releasing activity of ghrelin. It stimulates pituitary GH release by binding to GHSR-1a, increasing GH pulse amplitude without altering pulse frequency. It also increases IGF-1 levels, promotes nitrogen retention, and stimulates appetite. Unlike peptide GH secretagogues, it is orally bioavailable and has a long duration of action, maintaining elevated GH and IGF-1 levels with once-daily dosing.

IGF-1 LR3 is a synthetic 83-amino acid analog of IGF-1 (which has 70 amino acids) with an arginine at position 3 and a 13-amino acid extension at the N-terminus. These modifications reduce binding to IGF binding proteins (IGFBPs) by over 100-fold, resulting in dramatically higher bioavailability and potency compared to native IGF-1. It activates the IGF-1 receptor to stimulate the PI3K/Akt and MAPK/ERK pathways, promoting cell proliferation, differentiation, survival, and protein synthesis in muscle and other tissues.

PEG-MGF shares the same mechanism as MGF (satellite cell activation, muscle repair, neuroprotection) but has been modified through PEGylation, which involves covalent attachment of polyethylene glycol chains. This modification shields the peptide from enzymatic degradation, reduces renal clearance, and dramatically extends its half-life from minutes to hours. The sustained exposure allows for systemic distribution and more prolonged satellite cell activation.